Immunotec Inc. (TSX-V: IMM) has completed the plan of arrangement with 1111267 B.C. Ltd., a subsidiary of Immuno Holding S.A. de C.V., pursuant to which Immuno Holding has acquired all of the issued and outstanding common shares of Immunotec for $0.485 per share in cash. The transaction valued Immunotec’s equity at approximately $34.3 million.
Threadstone Advisors LLC and Blake Cassels & Graydon LLP acted as financial and legal advisor to Immunotec in connection with the transaction. Stikeman Elliot LLP acted as legal cousel to Immuno Holding.
Immuno Holding is a company led by Mauricio Domenzain in partnership with Nexxus Capital, one of the leading alternative asset managers in Mexico with a track record of almost 20 years of investing in and supporting successful growth companies.
“As a new member of the Immunotec family, I look forward to working collaboratively with Immunotec’s management and employees in Quebec, the U.S. and Mexico, as well as with its network of over 100,000 independent consultants, to fuel Immunotec’s growth,” said Domenzain. “Together, we will carry on the vision shared by the Company’s founders and Dr. Gustavo Bounous to position Immunocal® as a global nutritional choice and to continue to improve the lives of many more with this outstanding product.”
“As Immunotec celebrated last year its 20th year of commercialization and 40 years of research, this transaction represents an exciting new chapter in the history of Immunotec and in its continued path of growth and success,” Charlie Orr, CEO of Immunotec.
Immunotec is a Canadian-based company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S., Mexico, the Dominican Republic, the United Kingdom and Ireland. The company offers an extensive line of nutritional, skin care and wellness products targeting health, weight management, energy and physical performance.
photo credit: Immunotec